SCHEMBL3669237

SCHEMBL3669237

Cc1cc(NC(O)C(C)O)nc(-c2ccc(Br)c(F)c2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.64
NPC1 O15118 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
HSP90AA1 P07900 1/20 0.48
GAA P10253 1/20 0.48
ALOX15 P16050 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GPR119 Q8TDV5 1/20 0.43
ABCG2 Q9UNQ0 8/20 0.37
ABCC1 P33527 4/20 0.37
ABCB1 P08183 3/20 0.37
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPT P10636 1/20 0.34
RECQL P46063 1/20 0.34
FFAR1 O14842 1/20 0.33
KIF11 P52732 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL390885 0.78 CYP1A2 (1.00) CYP1A2NPC1ALDH1A1LMNAHSP90AA1
SCHEMBL390886 0.78 CYP1A2 (1.00) CYP1A2NPC1ALDH1A1LMNAHSP90AA1
SCHEMBL13309907 0.69 CYP1A2 (0.45) CYP1A2NPC1ALDH1A1LMNAHSP90AA1
SCHEMBL22578238 0.67 CYP1A2 (0.47) CYP1A2NPC1ALDH1A1LMNAHSP90AA1
SCHEMBL387105 0.64 SMN1; SMN2 (0.73) CYP1A2NPC1ALDH1A1LMNAHSP90AA1
SCHEMBL20597553 0.63 MEN1 (0.46) CYP1A2NPC1ALDH1A1LMNARAB9A
SCHEMBL25384005 0.62 L3MBTL1 (0.57) CYP1A2NPC1LMNARAB9ASMN1; SMN2
SCHEMBL20597903 0.62 CYP1A2 (0.41) CYP1A2NPC1RAB9ASMN1; SMN2KIF11
SCHEMBL22578241 0.61 MEN1 (0.51) ALDH1A1LMNAGAASMN1; SMN2MEN1
SCHEMBL23609299 0.61 CYP1A2 (0.42) CYP1A2NPC1ALDH1A1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816364-B2 GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto ARENA PHARMACEUTICALS, INC. (US) 2010-10-19 US disclosed
US-20090270422-A1 GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto ARENA PHARMACEUTICALS, INC. 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270422-A1 GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto GPR119, GLP1R, GPR4 CYP1A2 2735/4885NPC1 2006/4885ALDH1A1 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.